Neuphoria Therapeutics Inc.
NEUP
$4.61
$0.020.44%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | 16.89% | 34.84% | -- |
| Gross Profit | -- | -- | -17.10% | 1,216.73% | 132.57% |
| SG&A Expenses | -18.48% | 12.01% | -13.07% | 17.67% | 5.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.22% | 58.44% | 6.30% | 26.49% | -8.93% |
| Operating Income | 30.95% | -58.44% | -6.54% | 600.13% | 23.80% |
| Income Before Tax | 194.70% | -960.97% | -236.27% | 504.84% | 57.91% |
| Income Tax Expenses | -400.00% | 73.68% | -681.82% | -595.12% | 133.33% |
| Earnings from Continuing Operations | 195.92% | -1,130.93% | -230.62% | 505.39% | 57.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 195.92% | -1,130.93% | -230.62% | 505.39% | 57.33% |
| EBIT | 30.95% | -58.44% | -6.54% | 600.13% | 23.80% |
| EBITDA | 32.54% | -61.28% | -6.75% | 644.74% | 24.72% |
| EPS Basic | 133.31% | -612.54% | -39.38% | 331.35% | 76.78% |
| Normalized Basic EPS | 155.11% | -514.19% | 19.68% | 331.03% | 77.09% |
| EPS Diluted | 56.79% | -612.54% | -39.37% | 331.30% | 66.25% |
| Normalized Diluted EPS | 155.11% | -514.19% | 19.68% | 331.03% | 77.09% |
| Average Basic Shares Outstanding | 187.98% | 72.76% | 137.20% | 75.24% | 83.74% |
| Average Diluted Shares Outstanding | 187.98% | 72.76% | 137.20% | 75.24% | 83.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |